Literature DB >> 23053563

Onychomycosis: modern diagnostic and treatment approaches.

Georgi Tchernev1, Plamen Kolev Penev, Pietro Nenoff, Liliya Georgieva Zisova, José Carlos Cardoso, Teodora Taneva, Gabriele Ginter-Hanselmayer, Julian Ananiev, Maya Gulubova, Reni Hristova, Desislava Nocheva, Claudio Guarneri, G Martino, Nobuo Kanazawa.   

Abstract

The medical term onychomycosis should be understood as chronic infection of the nails caused by a fungus. The most common causative agents are the dermatophytes and Candida species. The less common are certain types of moulds (nondermatophyte moulds or NDMs). In approximately 60-80 % of the cases, onychomycosis is due to dermatophytes. Among dermatophytes, the most often isolated causative pathogen is Trichophyton (T.) rubrum. Other common species are T. interdigitale (formerly T. mentagrophytes), Epidermophyton floccosum, and T. tonsurans. The most significant yeasts causing onychomycosis are Candida albicans and Candida parapsilosis. Predisposing factors for onychomycosis include mainly diseases such as diabetes mellitus, peripheral vascular arterial disease, chronic venous insufficiency, polyneuropathies of diverse etiologies, and immunosuppression, e.g., myeloproliferative diseases (such as lymphoma and paraproteinemia), HIV/AIDS, etc. Other factors facilitating the fungal infection are frequent trauma in professional sportsmen, often accompanied by excessive perspiration. The diagnostic methods that are often applied in different dermatologic departments and ambulatory units are also different. This precludes the creation of a unified diagnostic algorithm that could be used everywhere as a possible standard. In most of the cases, the method of choice depends on the specialist's individual experience. The therapeutic approach depends mostly on the fungal organism identified by the dermatologist or mycologist. This review hereby includes the conventional as well as the newest and most reliable and modern methods used for the identification of the pathogens causing onychomycosis. Moreover, detailed information is suggested, about the choice of therapeutic scheme in case whether dermatophytes, moulds, or yeasts have been identified as causative agents. A thorough discussion of the schemes and duration of the antifungal therapy in certain groups of patients have been included.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23053563     DOI: 10.1007/s10354-012-0139-3

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  56 in total

1.  Differentiation of Aeromonas isolated from drinking water distribution systems using matrix-assisted laser desorption/ionization-mass spectrometry.

Authors:  Maura J Donohue; Jennifer M Best; Anthony W Smallwood; Mitchell Kostich; Mark Rodgers; Jody A Shoemaker
Journal:  Anal Chem       Date:  2007-02-02       Impact factor: 6.986

2.  Partial surgical avulsion of the nail in onychomycosis.

Authors:  R Baran; R J Hay
Journal:  Clin Exp Dermatol       Date:  1985-09       Impact factor: 3.470

3.  [Fungal nail infections - an update. Part 2 - From the causative agent to diagnosis - conventional and molecular procedures].

Authors:  P Nenoff; G Ginter-Hanselmayer; H-J Tietz
Journal:  Hautarzt       Date:  2012-02       Impact factor: 0.751

Review 4.  [Innovations in dermatologic laser therapy].

Authors:  U Hohenleutner
Journal:  Hautarzt       Date:  2010-05       Impact factor: 0.751

5.  Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study.

Authors:  Jean-Claude Roujeau; Bardur Sigurgeirsson; Hans-Christian Korting; Helmut Kerl; Carle Paul
Journal:  Dermatology       Date:  2004       Impact factor: 5.366

Review 6.  Trichophyton mentagrophytes sive interdigitale? A dermatophyte in the course of time.

Authors:  Pietro Nenoff; Jürgen Herrmann; Yvonne Gräser
Journal:  J Dtsch Dermatol Ges       Date:  2007-03       Impact factor: 5.584

7.  Comparison of diagnostic methods in the evaluation of onychomycosis.

Authors:  Jeffrey M Weinberg; Evelyn K Koestenblatt; William D Tutrone; Hillarie R Tishler; Lily Najarian
Journal:  J Am Acad Dermatol       Date:  2003-08       Impact factor: 11.527

8.  Increased prevalence of onychomycosis among psoriatic patients in Israel.

Authors:  Vera Leibovici; Klilah Hershko; Arieh Ingber; Maria Westerman; Nurit Leviatan-Strauss; Malka Hochberg
Journal:  Acta Derm Venereol       Date:  2008       Impact factor: 4.437

9.  Fungal foot infection, cellulitis and diabetes: a review.

Authors:  I R Bristow; M C Spruce
Journal:  Diabet Med       Date:  2009-05       Impact factor: 4.359

10.  Toenail abnormalities and onychomycosis in chronic venous insufficiency of the legs: should we treat?

Authors:  A Shemer; N Nathansohn; B Kaplan; H Trau
Journal:  J Eur Acad Dermatol Venereol       Date:  2008-03       Impact factor: 6.166

View more
  13 in total

1.  Progredient dermatophytosis and nevus anemicus: a pathogenetic mediated relationship.

Authors:  G Tchernev; A A Chokoeva
Journal:  Wien Med Wochenschr       Date:  2016-08-30

2.  Correlation of clinical characteristics, by calculation of SCIO index, with the laboratory diagnosis of onychomycosis.

Authors:  Eleonora Dubljanin; Aleksandar Dzamic; Isidora Vujcic; Stefan Mijatovic; Teodora Crvenkov; Sandra Sipetic Grujicic; Ivana Colovic Calovski
Journal:  Braz J Microbiol       Date:  2022-01-08       Impact factor: 2.476

3.  [Molecular biological detection of dermatophytes in clinical samples when onychomycosis or tinea pedis is suspected. A prospective study comparing conventional dermatomycological diagnostics and polymerase chain reaction].

Authors:  I Winter; S Uhrlaß; C Krüger; J Herrmann; G Bezold; A Winter; S Barth; J C Simon; Y Gräser; P Nenoff
Journal:  Hautarzt       Date:  2013-04       Impact factor: 0.751

4.  Tinea atypica: report of nine cases.

Authors:  Liliya Georgieva Zisova; Hristo Petrov Dobrev; Georgi Tchernev; Kristina Semkova; Anastasia Atanasova Aliman; Kristina Ivanova Chorleva; Antonina Teneva Chapanova; Nina Ivanova Vutova; Uwe Wollina
Journal:  Wien Med Wochenschr       Date:  2013-08-15

5.  Efinaconazole: first global approval.

Authors:  Trina Patel; Sohita Dhillon
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

6.  Anti-trichophyton activity of protocatechuates and their synergism with fluconazole.

Authors:  Luciana Arantes Soares; Fernanda Patrícia Gullo; Janaina de Cássia Orlandi Sardi; Nayla de Souza Pitangui; Caroline Barcelos Costa-Orlandi; Fernanda Sangalli-Leite; Liliana Scorzoni; Luis Octávio Regasini; Maicon Segalla Petrônio; Patrícia Fernanda Souza; Dulce Helena Siqueira Silva; Maria José Soares Mendes-Giannini; Ana Marisa Fusco-Almeida
Journal:  Evid Based Complement Alternat Med       Date:  2014-06-18       Impact factor: 2.629

Review 7.  Novel Drug Delivery Strategies for the Treatment of Onychomycosis.

Authors:  Rupinder K Dhamoon; Harvinder Popli; Madhu Gupta
Journal:  Pharm Nanotechnol       Date:  2019

8.  Synergistic combination of violacein and azoles that leads to enhanced killing of major human pathogenic dermatophytic fungi Trichophyton rubrum.

Authors:  S Anju; Nishanth S Kumar; B Krishnakumar; B S Dileep Kumar
Journal:  Front Cell Infect Microbiol       Date:  2015-08-11       Impact factor: 5.293

9.  Psychosocial perception of adults with onychomycosis: a blinded, controlled comparison of 1,017 adult Hong Kong residents with or without onychomycosis.

Authors:  Henry Hl Chan; Emma T Wong; Chi Keung Yeung
Journal:  Biopsychosoc Med       Date:  2014-07-15

10.  Ellagic Acid Inhibits Trichophyton rubrum Growth via Affecting Ergosterol Biosynthesis and Apoptotic Induction.

Authors:  Zhi-Jian Li; Amima Abula; Abudumijiti Abulizi; Chun Wang; Qin Dou; Youlidouzi Maimaiti; Abudoujilili Abudouaini; Shi-Xia Huo; Silafu Aibai
Journal:  Evid Based Complement Alternat Med       Date:  2020-10-27       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.